3.

药理组小鼠肿瘤酶消化悬液细胞分析。Gefitinib相对于DMSO组，PD-1阳性CD4⁺ T细胞比例差异不明显（A），FoxP3阳性CD4⁺/CD25⁺ T细胞比例差异不具有统计学意义（B）。Gefitinib组样本PD-1阳性CD4⁺ T为73.44%（C），同源DMSO组样本PD-1阳性CD4⁺ T为73.76%（D）。^*P＜0.05。

FACS analysis the tumor cell suspensions about pharmacological blockade of EGFR. Systemic administration by gefitinib or 10% DMSO for 1 week, the proportion of PD-1 positive CD4⁺ T cells had no difference (A), so as the FoxP3 positive CD4⁺CD25⁺ T cell ratio (B). A sample from gefitinib group, the PD-1 positive CD4⁺ T ratio was 73.44% (C), the ratio of DMSO sample was 55.33% (D). ^*P < 0.05.